Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

Abstract Background Compound epidermal growth factor receptor (EGFR) mutations are less responsive to tyrosine kinase inhibitors (TKIs) than single EGFR mutations in non-small cell lung cancer (NSCLC). However, the detailed clinical characteristics and prognosis of various compound EGFR mutations re...

Full description

Bibliographic Details
Main Authors: Weixin Zhao, Ailing Song, Yang Xu, Qian Wu, Cuicui Liu, Jiani C. Yin, Qiuxiang Ou, Xue Wu, Yang Shao, Xinmin Zhao
Format: Article
Language:English
Published: BMC 2023-02-01
Series:BMC Medicine
Subjects:
Compound EGFR mutations
Non-small cell lung cancer
Tyrosine kinase inhibitors
Precision medicine
Resistant mechanism
Online Access:https://doi.org/10.1186/s12916-023-02768-z

Internet

https://doi.org/10.1186/s12916-023-02768-z

Similar Items